Chrystyn H.,University of Huddersfield |
Small M.,REAL WORLD |
Milligan G.,REAL WORLD |
Higgins V.,REAL WORLD |
And 2 more authors.
Respiratory Medicine | Year: 2014
Objective To examine the relationships between inhaler satisfaction, treatment compliance and health status in patients with chronic obstructive pulmonary disease (COPD). Methods In a large, multinational, cross-sectional, real-world survey, respiratory specialists and primary care physicians provided information on six consecutive patients with COPD, who were then asked to complete a questionnaire. Physician-assessed compliance was scored (5-point Likert scale) and patients rated overall satisfaction with their maintenance inhaler (7-point Likert scale). Health status assessments included frequency of exacerbations and hospitalizations due to exacerbations in the past 12 months. Results The analysis included 1443 patients (71.8% male; mean age 65.2 years). Patients' overall satisfaction with their inhaler was significantly associated with treatment compliance (χ2 - df = 89.7; p < 0.001). Male gender (χ2 - df = 2.9; p < 0.05) and fewer maintenance drugs (χ2 - df = 17.7; p < 0.001) were also associated with compliance; age and breathlessness severity were not. Attributes influencing inhaler satisfaction mainly related to durability, ergonomics and ease of use. Small but statistically significant associations were observed between increasing treatment compliance and fewer exacerbations (R2 = 0.037; p < 0.001) and fewer hospitalizations due to exacerbations (R2 = 0.025; p < 0.001). There was a direct association between inhaler satisfaction and fewer exacerbations (R2 = 0.03; p < 0.001). Conclusions Treatment compliance appears to be modestly associated with inhaler satisfaction, better health status and less frequent COPD exacerbations, although other factors are also likely to be involved. Durability, ergonomics and ease-of-use are inhaler attributes that influence patient satisfaction. © 2013 Published by Elsevier Ltd.
Almirall | Date: 2014-02-24
Pharmaceutical preparations for the treatment of skin diseases; medicated dermatological preparations and substances; pharmaceutical preparations for the treatment of migraine and respiratory disorders. Pharmaceutical research and development. Providing medical information.
Astrazeneca and Almirall | Date: 2014-06-03
Pharmaceutical preparations for the treatment of respiratory diseases. Inhalers for medical purposes.
Almirall | Date: 2014-07-16
Pharmaceutical preparations for treating respiratory diseases, supplied in pre-filled inhalers. Inhalers for medical purposes.
Called the CMV (capillary microextraction of volatiles), the device can sample air by drawing just a small amount of air through it. When sent to a laboratory for analysis using gas chromatography-mass spectrometry, volatile organic compounds (VOCs) are identified including those associated with the presence of bacteria, mold, carcinogens, and much more. The CMV could potentially be used in medical diagnostics simply by breathing through it—offering an inexpensive, non-invasive method for disease-detection by detecting VOCs in lungs. Because of its portability, low cost and proven sensitivity, the CMV can impact nearly all industries including medicine, law enforcement, shipping, insurance, and even private in-home use. FIU Inventor Jose Almirall, a chemist and director of the FIU International Forensic Research Institute, and alumnus Digno Caballero have formed IAD-x, LLC to further develop the device and expand research with the intent to put analytical chemistry within reach for the average person. Their efforts were on display early this spring at the eMerge Americas technology conference at the Miami Beach Convention Center earlier this year—a platform connecting revolutionary startups, cutting-edge ideas, global industry leaders and investors worldwide. The IAD-x collaboration is revolutionizing the field of analytical chemistry while helping to foster economic growth and employment opportunities. The team was selected by the National Science Foundation to participate in the Innovation Corps Teams Program (I-Corps) this past summer. The program connects NSF-funded researchers with the business community and entrepreneurs to promote innovation and technology transfer. Although initially developed to detect explosives, additional applications and potential markets became apparent through the NSF-funded I-Corps customer discovery process. "I recommend any faculty member wanting to explore commercialization of science and technology to consider going through the I-Corps program," Almirall said. "The I-Corps team of a student or post-doc, a business mentor and the PI is provided with the tools necessary to begin to evaluate whether a scientific discovery can be turned into a viable business." Still in the early stages of development, the researchers are exploring market opportunities for industry applications. All of their efforts are concentrated at FIU's Modesto A. Maidique Campus in Miami, Fla. where IAD-x is being incubated. Explore further: Engineering new lighting and display technology